APA (7th ed.) Citation

YC, L., BH, L., M, M., YS, W., TH, H., SV, A., & CP, W. (2025). The fourth-generation EGFR tyrosine kinase inhibitor BLU-945 resensitizes ABCG2-overexpressing multidrug-resistant non-small cell lung cancer cells to cytotoxic anticancer drugs. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 215, 107337. https://doi.org/10.1016/j.ejps.2025.107337

Chicago Style (17th ed.) Citation

YC, Li, Lin BH, Murakami M, Wu YS, Hung TH, Ambudkar SV, and Wu CP. "The Fourth-generation EGFR Tyrosine Kinase Inhibitor BLU-945 Resensitizes ABCG2-overexpressing Multidrug-resistant Non-small Cell Lung Cancer Cells to Cytotoxic Anticancer Drugs." European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences 215 (2025): 107337. https://doi.org/10.1016/j.ejps.2025.107337.

MLA (9th ed.) Citation

YC, Li, et al. "The Fourth-generation EGFR Tyrosine Kinase Inhibitor BLU-945 Resensitizes ABCG2-overexpressing Multidrug-resistant Non-small Cell Lung Cancer Cells to Cytotoxic Anticancer Drugs." European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, vol. 215, 2025, p. 107337, https://doi.org/10.1016/j.ejps.2025.107337.